AHA

This channel contains news about the American Heart Association (AHA), including coverage of its annual meeting and guidelines. AHA is a leading resource for cardiology information, both consumer and professional.

COVID-19 cardiology related content continues to be among the top performers on the DAIC website in November 2020. TAVR also topped headlines with Boston Scientific taking its Lotus valve off the market and a review of TAVR registry data showing it is now the dominant method of aortic valve replacement in the United States. #DAIC

Feature | Cardiovascular Business | Dave Fornell, Editor

December 1, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

December 01, 2020

One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session. #AHA2020 #AHA20 #AHA

News | Stents

Biodegradable Drug Eluting Coronary Stent Noninferior to Xience or Promus Durable Polymer Stents

November 24, 2020 — One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT ...

November 24, 2020

Videos | Coronavirus (COVID-19)

VIDEO: Lingering Myocardial Involvement After COVID-19 Infection

Aaron Baggish, M.D., director of the cardiovascular performance program, Massachusetts General Hospital. He was on a ...

November 18, 2020

Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients. COVID-19 patients with cardiovascular diseases have in-hospital mortality rates of between 25 to 38 percent. #AHA #AHA20 #AHA2020 #COVID19 #Coronavirus #SARSCoV2

News | Coronavirus (COVID-19) | Dave Fornell, Editor

COVID-19 Patients With Cardiovascular Disease Have In-hospital Mortality Rates of 25 to 38 Percent

November 18, 2020 — A late-breaking study at the 2020 American Heart Association (AHA) Scientific Sessions showed nearly ...

November 18, 2020

RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm

News

Rivaroxaban is Comparable to Warfarin for Bioprosthetic Mitral Valves and AF

November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial ...

November 18, 2020

Black patient being tested for COVID-19 using a nasal swab PCR test. black adults with COVID-19 were far more likely to be hospitalized than their white counterparts according to data from the AHA COVID-19 Cardiovascular Disease Registry. #AHA #AHA20 #AHA2020 #COVID19 #SARSCoV2

Feature | Coronavirus (COVID-19)

COVID-19 Cardiovascular Registry Details Disparities Among Hospitalized Patients

November 18, 2020 -- A new American Heart Association (AHA) collaborative model for COVID-19 (SARS-CoV-2) research ...

November 18, 2020

Videos | Atrial Fibrillation

VIDEO: Screening for Atrial Fibrillation Using Single Lead ECG in the VITAL-AF Trial

Steven Lubitz, M.D., MPH, cardiac electrophysiologist, Massachusetts General Hospital, presented the late-breaking VITAL ...

November 18, 2020

Women’s Heart Attack Research Program (HARP) shows combining OCT and cardiac MRI can detect the underlying cause of heart attack in women who did not have blocked arteries

News | Cardiac Imaging

OCT Combined with MRI Can Identify Cause of Unexplained Heart Attacks in Women

November 17, 2020 — Diagnostic imaging techniques were able to find the underlying cause of heart attack in many women ...

November 17, 2020

Omega-3 fish oil supplements did not help patients after a heart attack in AHA 2020 study. #AHA #AHA20 #AHA2020. Getty Images

News | Pharmaceuticals

Omega-3s Do Not Reduce Cardiac Events in Recent Heart Attack Survivors

November 17, 2020 — A daily dose of omega-3 fatty acids did not reduce the risk of cardiac events, including secondary ...

November 17, 2020

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020

News | Cath Lab

Ticagrelor Not Superior to Clopidogrel in Reducing Heart Attacks During PCI

November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to ...

November 16, 2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

News | Atrial Fibrillation

Patients at Risk of AF May Need Extra Monitoring After Heart Surgery

November 16, 2020 — Atrial fibrillation (AF), an irregular heartbeat that can increase the likelihood of stroke, was ...

November 16, 2020

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being. #AHA #AHA2020 #AHA20

News | Atrial Fibrillation

Early Invasive Intervention for Atrial Fibrillation May Improve Patient Outcomes and Provide a Better Quality of Life

November 16, 2020 – Doctors from the Montreal Heart Institute (MHI) presented new data that shows catheter ablation as ...

November 16, 2020

The AHA 2020 late-breaking SAMSON Trial found side effects reported from statins are real, but appear due to the psychological rather than the pharmacological effects of the cholesterol lowering drugs. #AHA20 #AHA2020

News | Pharmaceuticals

Side Effects Attributed to Statins Same for Those Taking a Placebo

November 16, 2020 — Among patients who stopped taking their cholesterol-lowering statin medication due to side effects ...

November 16, 2020

News | Pharmaceuticals

New Novartis Data for Inclisiran Shows Effective and Sustained LDL-C Reduction at 17 Regardless of Age or Gender

November 16, 2020 — Novartis announced results from two pooled post-hoc analyses of Phase III ORION-9, -10 and -11 ...

November 16, 2020

Feature | AHA | Dave Fornell, Editor

American Heart Association 2020 Late-breaking Trial Presentations

Here is a list of the American Heart Association (AHA) late-breaking clinical trial presentations at the 2020 Virtual ...

November 20, 2020